Blow For CureVac As COVID-19 Vaccine Hits 47% Efficacy
Second Interim Readout Disappoints
Executive Summary
CureVac is not throwing in the towel just yet, but the odds are stacked against a successful end result.
You may also be interested in...
CureVac Still Hopes Variants Could Win Favor For COVID-19 Vaccine
Patients 18-60 had a protection rate of 53%, but there were too few cases among those older than 60 – a crucial subgroup – in HERALD to draw conclusions about the vaccine’s efficacy among older people.
Crucial Information Coming On GSK's Investor Day Includes Consumer Health Spin-Out Details
Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.
Six Questions For GSK Ahead Of Crucial Investor Day
Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.